Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00366262 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

A Phase 1 study of Healthy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00366262: Completed Phase 1 study of Healthy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

NCT00366262 is a Phase 1 study of Healthy that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00366262, a Phase 1 study of Healthy, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Naproxen
  • DRUG PLA-695

Study Locations (1)

Texas

  • - Houston

Trial Details

FieldValue
Start Date 2006-06
Est. Completion 2007-03
Phase Phase 1

What the finished NCT00366262 record still lists

NCT00366262 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00366262 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00366262 about?

NCT00366262 is a clinical study titled "Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen". The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

What is the current status of trial NCT00366262?

This trial is currently completed. It is a Phase 1 study. The study started on 2006-06. Estimated completion is 2007-03.

What conditions does trial NCT00366262 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00366262?

The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), PLA-695 (DRUG).

Who is sponsoring clinical trial NCT00366262?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00366262 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00366262, the US trial registry maintained by the National Library of Medicine. NCT00366262 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.